Ken Griffin Synaptogenix, Inc. Call Options Transaction History
Citadel Advisors LLC
- $509 Billion
- Q1 2024
Call Options
0 transactions
Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
---|
Others Institutions Holding SNPX
# of Institutions
25Shares Held
955KCall Options Held
0Put Options Held
0-
Jim Simons Renaissance Technologies LLC | New York, Ny401KShares$1.65 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA154KShares$634,8750.0% of portfolio
-
Two Sigma Securities, LLC New York, NY83.4KShares$342,8100.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA68.5KShares$281,6250.0% of portfolio
-
Cannell & Co. New York, NY30KShares$123,3000.0% of portfolio
About Synaptogenix, Inc.
- Ticker SNPX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 6,840,630
- Market Cap $28.1M
- Description
- Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodeg...